Home / Research library / VIP
VIP: molecular data, studies & sources
VIP is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C147H237N43O43S
- Molecular weight (MW)
- 3326.8 g/mol
- PubChem compound ID
- 53314964
- Record title
- Vasoactive intestinal peptide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 53314964 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- (2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid
- InChIKey
- VBUWHHLIZKOSMS-RIWXPGAOSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N
Identifiers & sequence
- PubChem CID
- 53314964
- CAS Registry Number
- 37221-79-7via ChemIDplus, FDA GSRS
- FDA UNII
- 6J2WVD66KR
- InChIKey
- VBUWHHLIZKOSMS-RIWXPGAOSA-N
Peptide sequence · 28 residues (one-letter code; X marks a residue without a one-letter code)
HSDAVFTDNYTRLRKQMAVKKYLNSILN
Condensed notation with terminal groups and non-standard residues
H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-OH
Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 3324.7401 Da |
|---|---|
| Heavy atoms | 234 |
| Hydrogen-bond donors | 51 |
| Hydrogen-bond acceptors | 48 |
| Rotatable bonds | 113 |
| Topological polar surface area | 1447.9 Ų |
| Calculated logP (Crippen) | -14.62 |
| Rings | 4 |
| Stereocenters | 31 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Vasoactive intestinal peptide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
7 registered studies matched.
- By highest phase
- Phase 1 · 1Not applicable · 6
- By registry status
- Completed · 7
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine PatientsNCT04260035 · start 2020-05-19 · primary completion 2020-09-15 | Not applicableCompleted | Migraine · Pain · Neurologic Manifestations · Signs and Symptoms · Brain Diseases · Central Nervous System Diseases | Danish Headache Center21 participants |
| The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy VolunteersNCT03989817 · start 2019-06-14 · primary completion 2020-06-30 | Not applicableCompleted | Headache Disorders | Danish Headache Center12 participants |
| Effect of PACAP38/VIP on Migraineurs Measured by Magnetic ResonanceNCT01471990 · start 2011-05 · primary completion 2012-06 | Not applicableCompleted | Migraine Without Aura | Glostrup University Hospital, Copenhagen24 participants |
| Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in MigraineursNCT00272896 · start 2004-10 | Not applicableCompleted | Headache · Migraine · Vasoactive Intestinal Peptide · Ultrasonography, Doppler, Transcranial | Danish Headache Center12 participants |
| Experimental Headache Induced by Vasoactive Intestinal PolypeptideNCT00255320 · start 2003-12 | Not applicableCompleted | Healthy Volunteers, Headache, Migraine, Hemodynamics, VIP, SPECT, Ultrasound | Danish Headache Center12 participants |
| Vasoactive Intestinal Peptide in COPDNCT00464932 · start 2003-06 | Not applicableCompleted | COPD · Pulmonary Hypertension | Medical University of Vienna34 participants |
| Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and SepsisNCT00004494 · start 1998-09 | Phase 1Completed | Sepsis · Respiratory Distress Syndrome · Respiratory Distress Syndrome, Adult | Stony Brook University18 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Vasoactive intestinal peptide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection.
Roy JB, Petrone RL, Said SI et al. · The Journal of urology · 1990
PMID 2405186 · DOI: 10.1016/s0022-5347(17)39939-1
Human studies that measured Vasoactive intestinal peptide or used it as a comparator
Indexed as human studies in PubMed, but participants were not given Vasoactive intestinal peptide as the studied intervention, or the record does not establish that they were. They describe measurements or comparisons, not the effect of administering the compound.
- Human study · PubMed trial index Endogenous level measured · not given
Role of tear vasoactive intestinal peptide on dry eyes after laser keratorefractive surgery.
Kang Y, Hu Q, Li X et al. · BMC ophthalmology · 2023
PMID 37081425 · DOI: 10.1186/s12886-023-02857-w
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
Vasoactive intestinal peptide.
Said SI · Journal of endocrinological investigation · 1986
PMID 2872248 · DOI: 10.1007/BF03348097
- Review · secondary evidence
Vasoactive Intestinal Peptide-Secreting Tumors: A Review.
Siddappa PK, Vege SS · Pancreas · 2019
PMID 31609932 · DOI: 10.1097/MPA.0000000000001402
- Review · secondary evidence
Vasoactive intestinal peptide secreting tumour: An overview.
Una Cidon E · World journal of gastrointestinal oncology · 2022
PMID 35582098 · DOI: 10.4251/wjgo.v14.i4.808
VIP supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
VIP for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino ClubUSD | 10mg Vial1 recorded offers | 10mg Vial · $49.99Stale observation · Checked Oct 14, 2026Supplier listing, VIP 10mg Vial, Amino Club, opens in a new tab |
| Amino USAUSD | 5mg Vial1 recorded offers | 5mg Vial · $48.00Checked Nov 6, 2026Supplier listing, VIP 5mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 5mg Vial1 recorded offers | 5mg Vial · $64.99Checked Nov 6, 2026Supplier listing, VIP 5mg Vial, Cenexa Labs, opens in a new tab |
| Blank PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $75.00Stale observation · Checked Sep 30, 2026Supplier listing, VIP 10mg Vial, Blank Peptides, opens in a new tab |
| LA PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $59.99Checked Nov 3, 2026Supplier listing, VIP 10mg Vial, LA Peptides, opens in a new tab |
Reference sources & further reading
- PubChem compound record 53314964 — chemical identity and structure.
- FDA Global Substance Registration System: UNII 6J2WVD66KR — substance identity, names and codes.
- Wikipedia: Vasoactive intestinal peptide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
AOD-9604
C78H123N23O23S2
1815.1 g/mol · PubChem CID 71300630
2 selected publications · 0 human intervention studies
ARA-290
C51H84N16O21
1257.3 g/mol · PubChem CID 91810664
7 selected publications · 3 human intervention studies · 2 registered trials
Protein / peptide · highest stage: Phase 2
BPC-157
C62H98N16O22
1419.5 g/mol · PubChem CID 9941957
7 selected publications · 1 human intervention study · 3 registered trials
Protein / peptide · highest stage: Phase 1
KPV
C16H30N4O4
342.43 g/mol · PubChem CID 125672
8 selected publications · 0 human intervention studies
LL-37
C205H340N60O53
4493 g/mol · PubChem CID 16198951
4 selected publications · 0 human intervention studies · 2 registered trials
PTD-DBM
Molecular identity needs further verification
3 selected publications · 0 human intervention studies